Identification and validation of an immune-related gene prognostic signature for clear cell renal carcinoma

Clear Cell Renal Carcinoma (ccRCC) accounts for nearly 80% of renal carcinoma cases, and immunotherapy plays an important role in ccRCC therapy. However, the responses to immunotherapy and overall survival for ccRCC patients are still hard to predict. Here, we constructed an immune-related predictiv...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 869297
Main Authors Hua, Shan, Xie, Zhiwen, Zhang, Yongqing, Wu, Lei, Shi, Fei, Wang, Xingjie, Xia, Shujie, Dong, Shengli, Jiang, Juntao
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 22.07.2022
Subjects
clear cell renal carcinoma
immune microenvironment
immune-related genes
Immunology
immunotherapy
prognostic signature
Online AccessGet full text

Cover

More Information
Summary:Clear Cell Renal Carcinoma (ccRCC) accounts for nearly 80% of renal carcinoma cases, and immunotherapy plays an important role in ccRCC therapy. However, the responses to immunotherapy and overall survival for ccRCC patients are still hard to predict. Here, we constructed an immune-related predictive signature using 19 genes based on TCGA datasets. We also analyzed its relationships between disease prognosis, infiltrating immune cells, immune subtypes, mutation load, immune dysfunction, immune escape, etc. We found that our signature can distinguish immune characteristics and predict immunotherapeutic response for ccRCC patients with better prognostic prediction value than other immune scores. The expression levels of prognostic genes were determined by RT-qPCR assay. This signature may help to predict overall survival and guide the treatment for patients with ccRCC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors have contributed equally to this work
Edited by: Wendy Nevala, Mayo Clinic, United States
Reviewed by: Kimberly Sue Schluns, Kite Pharma, United States; Long Liu, First Affiliated Hospital of Zhengzhou University, China
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.869297